Alemtuzumab-induced halo naevus-like hypopigmentation - new insights into secondary skin autoimmunity in response to an immune cell-depleting antibody.

Böhm, M; Kemp, E H; Metze, D; Muresan, A M; Neufeld, M; Luiten, R M; Ruck, T

Böhm, M; Kemp, E H; Metze, D; Muresan, A M; Neufeld, M; Luiten, R M; Ruck, T.

Afiliação

Böhm M; Department of Dermatology, University of Münster, Münster, Germany.
Kemp EH; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Metze D; Department of Dermatology, University of Münster, Münster, Germany.
Muresan AM; Department of Dermatology, University of Münster, Münster, Germany.
Neufeld M; Department of Dermatology, University of Münster, Münster, Germany.
Luiten RM; Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands.
Ruck T; Clinic of Neurology with Institute for Translational Neurology, University of Münster, Münster, Germany.

J Eur Acad Dermatol Venereol ; 35(1): e28-e30, 2021 Jan.

Article em En | MEDLINE | ID: mdl-32579750

Assuntos

Alemtuzumab; Hipopigmentação; Nevo com Halo; Neoplasias Cutâneas; Alemtuzumab/efeitos adversos; Autoimunidade; Humanos; Hipopigmentação/induzido quimicamente

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Hipopigmentação / Nevo com Halo / Alemtuzumab Limite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google